DeBinge combines long-acting naltrexone, individual medical care, nursing support and one year of professional counseling in a private environment designed to give patients more stability, more time and more space to work on lasting change.
Medication can create valuable stability, but addiction also affects behavior, relationships, confidence, routines, health and the environment a person returns to. Our programme is designed around all of those pieces.
Treatment begins with the patient rather than a standard package. Medical history, substance use, medications, withdrawal requirements and recovery goals are assessed before treatment proceeds.
Sustained-release naltrexone is designed to provide medication support over an extended period without relying on remembering or deciding to take a tablet every day.
One year of professional counseling provides time to address triggers, habits, relationships, coping strategies and the life the patient wants to build after treatment.
Beginning treatment in Sandyport provides temporary distance from many of the people, places and routines associated with previous substance use.
Medical, nursing, counseling, client-support and operational professionals work around a structured patient journey rather than treating the implant as an isolated procedure.
We believe patients should understand what naltrexone can do, what it cannot guarantee, and the medical preparation and continued recovery work that treatment requires.
Addiction recovery often becomes difficult because a person is trying to change behavior while simultaneously dealing with craving, withdrawal, old routines and immediate access to the substance.
DeBinge is designed to create a more protected period in which some of those pressures can be reduced and recovery can become the priority.
Begin with consultation and clinical assessment so we understand what has been happening, what has already been tried and what needs to change.
Withdrawal and medication preparation are individualized. For opioid-dependent patients, an appropriate opioid-free period is essential before naltrexone.
When clinically appropriate, the sustained-release implant is placed by the medical team to provide continuing naltrexone delivery.
The next stage focuses on counseling, relationships, routines, mental wellbeing, purpose and preparation for life back home.
Naltrexone is an opioid-receptor antagonist. It has established clinical uses in opioid and alcohol use disorders and can reduce craving in suitable patients. For opioids, adequate naltrexone blockade also substantially reduces the usual opioid effects.
A sustained-release implant is designed to release medication gradually over an extended period rather than requiring daily oral dosing. The expected duration depends on the specific formulation and individual clinical circumstances.
Every patient follows an individualized medical pathway, but the overall journey is designed to be clear and understandable.
Tell us what is happening, what you are using, what you have tried before and what you want to change.
Your medical team assesses treatment suitability, medications, withdrawal needs and relevant health factors.
Once medically cleared, the implant is placed subcutaneously through a minor procedure using local anesthesia.
Follow-up and one year of professional counseling help turn medication-supported stability into longer-term change.
The implant is not presented as a substitute for psychological and behavioral recovery work.
Addiction can become connected with stress, trauma, relationships, boredom, routines, social environments, confidence and coping. Medication alone cannot automatically change those parts of life.
That is why the DeBinge programme includes one year of professional counseling, giving patients continued support after they return home.
We believe patients should be able to examine the scientific development behind long-acting naltrexone rather than relying only on marketing claims.
The O'Neil Long Acting Naltrexone Implant has been evaluated in U.S. clinical research involving Columbia University and the New York State Psychiatric Institute.
A pharmacokinetic and safety study is listed as completed on ClinicalTrials.gov, and further NIDA-supported clinical development has evaluated OLANI for opioid use disorder.
Naltrexone itself is an established medication for opioid and alcohol use disorders. Sustained-release implant formulations have their own evidence, duration and regulatory status depending on the product and jurisdiction.
Uses outside opioid and alcohol use disorder require individual medical assessment and may be off-label. DeBinge encourages patients to discuss expected benefits, limitations and alternative treatments with the clinical team.
Treatment is not delivered by a website or by an implant alone. DeBinge brings together clinical advisors, doctors, nursing, counseling and client-support professionals around the patient journey.
Developer of the O'Neil Long Acting Naltrexone Implant and a long-standing contributor to research and clinical development in sustained-release addiction treatment.
Psychiatrist and addiction-recovery specialist whose work has included clinical practice, public health, teaching and development of addiction services in The Bahamas.
Consultant psychiatrist with specialist experience in substance misuse, opioid dependence, detoxification and evidence-based addiction treatment.
Part of the senior medical team supporting patient assessment, clinical care and treatment delivery in The Bahamas.
Provides senior medical support with a focus on respectful, individualized care throughout the patient's clinical treatment journey.
Supports the programme with pharmacological knowledge and an understanding of mental-health and addiction care.
Physician supporting patients through a combination of medical care, mental-health awareness and culturally sensitive communication.
Leads DeBinge social communication and helps make information about treatment more accessible, understandable and approachable.
Provides strategic leadership focused on developing responsible treatment systems and improving access to addiction-recovery support.
Brings business, leadership and cross-disciplinary experience to the development and growth of DeBinge.
Leads nursing support with an emphasis on patient comfort, monitoring, communication and individualized care.
Leads the counseling component of recovery, helping patients work through emotional, behavioral and practical aspects of change.
Supports patients in translating recovery into meaningful goals, healthier routines and a clearer vision for life after treatment.
Helps coordinate the day-to-day patient experience and supports a comfortable, organized environment throughout the stay.
Supports DeBinge across digital marketing, content creation, website development, search visibility and partnership outreach, helping communicate the programme clearly and build relationships with professionals, media and referral partners.
Addiction often becomes connected with familiar surroundings, routines, relationships and everyday pressures.
Traveling to Nassau can create temporary physical distance from many of those cues while medical care and recovery become the immediate priority.
Sandyport offers warm weather, quiet surroundings and access to the natural environment. The purpose is not to present a holiday as treatment — it is to provide a calmer setting in which treatment, rest, counseling and reflection can take priority.
No. DeBinge combines medical assessment, sustained medication support where appropriate, nursing care and one year of professional counseling.
Naltrexone is an opioid antagonist. It does not produce an opioid-type high and does not create opioid physical dependence.
No. Treatment suitability must be assessed individually. Medical history, medications, liver health and substance-use history can all be relevant.
A person who remains physically dependent on opioids must complete an appropriate opioid-free period before naltrexone is started. Giving it too early can cause severe precipitated withdrawal.
No treatment can responsibly guarantee that. Naltrexone can provide important pharmacological support, but long-term recovery also depends on continued treatment, behavioral change, support and the patient's individual circumstances.
Recovery continues after the procedure. The DeBinge programme includes one year of professional counseling so that the patient can continue working on triggers, routines and longer-term change.
Tell us what you are dealing with, what you have tried before and what you want to change. A private consultation gives us the opportunity to understand your situation and explain the appropriate next steps.
This page provides general educational information and does not replace individual medical advice. Naltrexone is an established medication for opioid and alcohol use disorders; evidence, approved uses and regulatory status differ between oral, injectable and sustained-release implant formulations and between jurisdictions. Treatment suitability, withdrawal preparation and procedure timing must be determined by qualified healthcare professionals. Naltrexone does not make opioid overdose impossible, and attempting to overcome opioid blockade can be dangerous.
Delaware-based company responsible for U.S. marketing, communications and administration.
The Bahamas operating company works as a contracted service provider to DeBinge LLC, with treatment and local services delivered in Nassau, The Bahamas.
Ask about suitability, the medically supervised OLANI transition pathway, travel to Nassau and the year-long counselling programme.
